Cyberonics NCP Depression Indication May Be Tonic For Medtronic Blues
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will create a separate 214-member depression sales and marketing team for the NCP NeuroCybernetic Prosthesis vagus nerve stimulation system and have it in place by the beginning of 2002, or roughly six months before the company expects FDA approval for the indication, CEO Skip Cummins reported at a Sept. 21 teleconference.